689.50

3.99% -28.66

Pre-market: 687.50 -2.00 -0.29%

Regeneron Pharmaceuticals Inc (REGN)

Overview News Price History Option Chain Financials Why REGN Down? Discussions Forecast

Regeneron Pharmaceuticals Inc stock is traded at $689.50, with a volume of 790.68K. It is down -3.99% in the last 24 hours and up +3.86% over the past month. Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Previous Close:

$718.16

Open:

$709.94

24h Volume:

790.68K

Relative Volume:

0.92

Market Cap:

$75.38B

Revenue:

$14.20B

Net Income/Loss:

$4.41B

P/E Ratio:

18.01

EPS:

38.28

Net Cash Flow:

$3.54B

1W Performance:

+0.34%

1M Performance:

+3.86%

6M Performance:

-40.79%

1Y Performance:

-28.96%

1-Day Range:

$683.42

$712.46

1-Week Range:

$682.25

$748.29

52-Week Range:

$642.00

$1,211.20

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name

Regeneron Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(914) 847-7000

Address

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Employee

15,106

Twitter

@regeneron

Next Earnings Date

2025-02-04

Latest SEC Filings

REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REGN Regeneron Pharmaceuticals Inc	689.50	75.38B	14.20B	4.41B	3.54B	38.28
VRTX Vertex Pharmaceuticals Inc	495.42	127.22B	11.02B	-535.60M	-978.00M	-2.20
ARGX Argen X Se Adr	591.45	35.94B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.43	31.38B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.84	26.84B	3.32B	-860.46M	-1.04B	-8.32

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform
Jan-16-25	Downgrade	UBS	Buy → Neutral
Dec-10-24	Resumed	BofA Securities	Underperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Nov-14-24	Initiated	Citigroup	Neutral
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-12-24	Initiated	Bernstein	Outperform
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-21-23	Reiterated	Oppenheimer	Perform
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-24-23	Upgrade	Jefferies	Hold → Buy
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line
Sep-09-22	Upgrade	Jefferies	Underperform → Hold
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-06-22	Initiated	Jefferies	Underperform
May-23-22	Initiated	SVB Leerink	Outperform
Jan-05-22	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-22	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-15-21	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-09-21	Resumed	Wells Fargo	Overweight
Dec-07-21	Resumed	Cowen	Market Perform
Dec-06-21	Initiated	Goldman	Buy
Nov-19-21	Resumed	BMO Capital Markets	Outperform
Nov-05-21	Downgrade	The Benchmark Company	Buy → Hold
Jun-29-21	Initiated	H.C. Wainwright	Buy
Jan-25-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-13-21	Upgrade	The Benchmark Company	Hold → Buy
Jan-08-21	Upgrade	Citigroup	Neutral → Buy
Oct-05-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-20-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-09-20	Upgrade	SunTrust	Hold → Buy
May-26-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Apr-28-20	Downgrade	Citigroup	Buy → Neutral
Apr-17-20	Upgrade	The Benchmark Company	Hold → Buy
Apr-08-20	Initiated	The Benchmark Company	Hold
Mar-31-20	Initiated	Wolfe Research	Peer Perform
Feb-27-20	Initiated	Barclays	Overweight
Feb-26-20	Upgrade	Canaccord Genuity	Hold → Buy
Feb-26-20	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-25-20	Upgrade	Jefferies	Hold → Buy
Feb-11-20	Upgrade	Argus	Hold → Buy
Dec-24-19	Initiated	Raymond James	Mkt Perform
Dec-16-19	Downgrade	Evercore ISI	Outperform → In-line
Dec-13-19	Upgrade	Credit Suisse	Neutral → Outperform
Nov-12-19	Initiated	SunTrust	Hold
Nov-07-19	Upgrade	Citigroup	Neutral → Buy
Oct-17-19	Resumed	BofA/Merrill	Neutral
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy

View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

06:36 AM

Vestcor Inc Has $14.75 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

06:36 AM

04:42 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Citizens Financial Group Inc. RI - MarketBeat

04:42 AM

Mar 12, 2025

Lifeworks Advisors LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 12, 2025

Atlantic Union Bankshares Corp Has $2.85 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 12, 2025

Machina Capital S.A.S. Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 12, 2025

Generali Investments CEE investicni spolecnost a.s. Acquires New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 12, 2025

Jones Financial Companies Lllp Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 12, 2025

Bank Julius Baer & Co. Ltd Zurich Purchases 10,291 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 12, 2025

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Pharma Stock to Buy According to Hedge Funds? - Yahoo Finance

Mar 12, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Boosted by Wealthfront Advisers LLC - MarketBeat

Mar 12, 2025

Bullous Pemphigoid Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, NDA Approval, Treatment and Companies by DelveInsight - Barchart

Mar 12, 2025

Culture and cloud combine to harness data at Regeneron - CIO

Mar 12, 2025

PNC Financial Services Group Inc. Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 12, 2025

Callan Family Office LLC Invests $1.12 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 12, 2025

Mar 11, 2025

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem – Company Announcement - Financial Times

Mar 11, 2025

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem - Kilgore News Herald

Mar 11, 2025

Teen Scientists Win Big: Space Discovery, Rare Disease Treatment Lead $1.8M Regeneron Awards - StockTitan

Mar 11, 2025

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for ... - The Bakersfield Californian

Mar 11, 2025

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem - GlobeNewswire Inc.

Mar 11, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Up 4.7%What's Next? - MarketBeat

Mar 11, 2025

For Whom the Bell Tolls? The Impact of Wisconsin Bell v. United States ex rel. Todd Heath and United States v. Regeneron Pharmaceuticals Inc. on False Claims Act Litigation - Womble Bond Dickinson

Mar 11, 2025

Regeneron at Leerink Conference: Strategic Growth Beyond Eylea - Investing.com

Mar 11, 2025

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Markets Insider

Mar 11, 2025

Cornerstone Advisors LLC Acquires 1,900 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 11, 2025

Daiwa Securities Group Inc. Acquires 1,278 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 11, 2025

Raymond James Financial Inc. Invests $65.18 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 11, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Schaper Benz & Wise Investment Counsel Inc. WI - MarketBeat

Mar 11, 2025

Atria Investments Inc Has $4.73 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Mar 11, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by E Fund Management Co. Ltd. - MarketBeat

Mar 11, 2025

Mar 10, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Lessened by Bay Colony Advisory Group Inc d b a Bay Colony Advisors - MarketBeat

Mar 10, 2025